

**Table 4. Base case analysis**

	<b>Panitumumab Intervention</b>	<b>Trifluridine-tipiracil + bevacizumab Comparator 3<sup>rd</sup> line</b>
<b>Costs/resource use</b>		
Medicine acquisition	¶¶¶	¶¶¶
Administration	£3,400	£4,252
ctDNA screening	£250	
Best supportive care	£2,326	£1,505
total	¶¶¶	¶¶¶
Net cost		¶¶¶
<b>Clinical outcomes</b>		
Overall survival (months)		1.87
Progression free survival (months)		-1.68
Adverse events ≥ grade 3		-50.4%
¶¶¶ commercial in confidence figure removed		